Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Vafidemstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oryzon Gets FDA Feedback on Ph3 Borderline Protocol
    Oryzon Gets FDA Feedback on Ph3 Borderline Protocol

    17 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/17/3168803/0/en/ORYZON-Receives-Feedback-From-the-FDA-in-Response-to-the-Submitted-Phase-III-Protocol-in-Borderline-Personality-Disorder.html

    GLOBENEWSWIRE
    17 Oct 2025
    Share Share
    Oryzon Bolsters Patent Portfolio for Iadademstat and Vafidemstat
    Oryzon Bolsters Patent Portfolio for Iadademstat and Vafidemstat

    16 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/16/3150714/0/en/ORYZON-Strengthens-Patent-Portfolio-for-Iadademstat-and-Vafidemstat-with-New-Decisions-to-Grant.html

    GLOBENEWSWIRE
    16 Sep 2025
    Share Share
    ORYZON Bolsters Vafidemstat Patent Portfolio
    ORYZON Bolsters Vafidemstat Patent Portfolio

    14 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/14/3114679/0/en/ORYZON-Continues-to-Strengthen-its-Patent-Portfolio-for-Vafidemstat.html

    GLOBENEWSWIRE
    14 Jul 2025
    Share Share
    Oryzon Strengthens Patent Portfolio for Vafidemstat
    Oryzon Strengthens Patent Portfolio for Vafidemstat

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/21/3064596/0/en/ORYZON-Continues-to-Strengthen-its-Patent-Portfolio-for-Vafidemstat.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    ORYZON Reports Q4 2024 Financial Results and Corporate Update
    ORYZON Reports Q4 2024 Financial Results and Corporate Update

    27 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/27/3034283/0/en/ORYZON-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ended-December-31-2024.html

    GLOBENEWSWIRE
    27 Feb 2025
    Share Share
    ORYZON Publishes Ph2a Vafidemstat Results In Psychiatry Journal
    ORYZON Publishes Ph2a Vafidemstat Results In Psychiatry Journal

    14 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/14/3026608/0/en/ORYZON-Announces-Journal-Publication-of-Final-Phase-IIa-REIMAGINE-Results-with-Vafidemstat-in-Psychiatry-and-Clinical-Neurosciences.html

    GLOBENEWSWIRE
    14 Feb 2025
    Share Share